Combining radiation and chemo to make colon cancer removable
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your colon cancer has grown through the bowel wall but hasn't spread to other organs (stage T4NanyM0).
- Your cancer type is pMMR/MSS (a specific genetic type).
- You are well enough to be up and about (ECOG 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- You have not had previous treatment like chemo, radiation, or targeted therapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a combination of chemotherapy, targeted therapy, and immunotherapy, with or without radiation to the primary tumor, for people with advanced rectal cancer that has a specific genetic profile. It aims to see if adding radiation improves outcomes.
This trial tests a combination of radiation therapy with three drugs (an immunotherapy, a chemotherapy pill, and a targeted therapy) for advanced colorectal cancer. It aims to see if this combination can shrink tumors and improve outcomes for people whose cancer has not responded to standard treatments.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.